Use of Cannabis in Fetal Alcohol Spectrum Disorder

被引:6
|
作者
Koren, Gideon [1 ,2 ]
Cohen, Rana [1 ]
Sachs, Ornie [2 ]
机构
[1] Shamir Hosp, Motherisk Israel Program, IL-40700 Zerifin, Israel
[2] Ariel Univ, Adelson Fac Med, Ariel, Israel
关键词
cannabinoids; disruptive behavior; fetal alcohol spectrum behavior; BEHAVIOR; CHILDREN;
D O I
10.1089/can.2019.0056
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Fetal alcohol spectrum disorder (FASD) has been recently estimated to afflict up to 5% of American children. Most of these children exhibit different degrees of symptomatology of disruptive behaviors. Yet, there has been very little research on the efficacy and safety of pharmacological modalities, limited mostly to stimulants for attention deficit hyperactive disorder or second generation atypical antipsychotics for aggression. Recently, the use of cannabinoids has been described for symptoms related to autistic spectrum disorder with apparent favorable effects, as well as for other disruptive behaviors. The objective of our study was to follow up in a retrospective case series the effect of cannabis in children and young adults diagnosed with FASD. Methods: In two children and three FASD young adults with severe disruptive behavior, changes in behavior after cannabis use were measured by the parent version of the Nisonger Child Behavior Rating Form. Results: In all five cases, there was a highly statistical decrease in the disruptive behavior score from 18 +/- 1.0 before cannabis use to 6 +/- 2.1 after introduction of cannabis (p=0.0002). Discussion: In children and young adults with FASD, cannabis, mostly cannabidiol (CBD), has been associated with a marked and statistically significant improvement in serious disruptive behavior. These cases suggest that the efficacy and safety of CBD should be tested in well-controlled studies.
引用
收藏
页码:74 / 76
页数:3
相关论文
共 50 条
  • [41] THE DIFFERENTIAL DIAGNOSIS OF FETAL ALCOHOL SPECTRUM DISORDER
    Leibson, Tom
    Neuman, Gal
    Chudley, Albert E.
    Koren, Gideon
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2014, 21 (01): : E1 - E30
  • [42] Recent developments in fetal alcohol spectrum disorder
    Baker, Joshua J.
    Stoler, Joan M.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (01) : 77 - 81
  • [43] Subpopulations Are Vulnerable to Fetal Alcohol Spectrum Disorder
    Friedrich, M. J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (23): : 2273 - 2273
  • [44] Fetal alcohol spectrum disorder: reconsidering blame
    Abadir, Anna Maria
    Ickowicz, Abel
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2016, 188 (03) : 171 - 172
  • [45] Collaborative on Fetal Alcohol Spectrum Disorder Prevalence
    Warren, Kenneth R.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2020, 44 (04): : 814 - 814
  • [46] Evaluating the Cost of Fetal Alcohol Spectrum Disorder
    Popova, Svetlana
    Stade, Brenda
    Johnston, Mary
    MacKay, Holly
    Lange, Shannon
    Bekmuradov, Dennis
    Rehm, Juergen
    JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2011, 72 (01) : 163 - 164
  • [47] Cognitive aspects of fetal alcohol spectrum disorder
    Davis, Krista M.
    Gagnier, Karina Royer
    Moore, Timothy E.
    Todorow, Michelle
    WILEY INTERDISCIPLINARY REVIEWS-COGNITIVE SCIENCE, 2013, 4 (01) : 81 - 92
  • [48] Fetal Alcohol Spectrum Disorder and Iron Homeostasis
    Bradley, Regan
    Lakpa, Koffi L.
    Burd, Michael
    Mehta, Sunil
    Katusic, Maja Z.
    Greenmyer, Jacob R.
    NUTRIENTS, 2022, 14 (20)
  • [49] Aboriginal women, alcohol and the road to fetal alcohol spectrum disorder
    Hayes, Lorian G.
    MEDICAL JOURNAL OF AUSTRALIA, 2012, 197 (01) : 21 - 23
  • [50] Fetal alcohol spectrum disorder prevention program: SBIRT's role in averting fetal alcohol spectrum disorders
    Manriquez, Maria
    Starer, Jacqueline
    Parisi, Vanessa
    Tracy, Erin
    McFadden, Tonya
    Penney, Lily
    BIRTH DEFECTS RESEARCH, 2019, 111 (12): : 829 - 834